secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055411
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen posts Q1 loss, details positive Phase 2 GA data, prices $115M notes
--------------------------------------------------------------------------

- Net loss of $(0.06) per share for Q1 2026; cash, cash equivalents, and restricted cash of $32.2M as of March 31, 2026.
- Phase 2 OCU410 trial for GA showed statistically significant 31% reduction in lesion growth at 12 months with optimal dose; 20% of patients showed no progression.
- Enrollment completed for OCU400 Phase 3 RP trial (N=140) and OCU410ST Stargardt Phase 2/3 trial (N=63); BLA submissions targeted by 2027.
- Priced $115M (up to $130M with over-allotment) of 6.75% Convertible Senior Notes due 2034 at 90% of par; conversion premium of 45% at $2.68/shr.
- Net proceeds ~$99.5M; $32.7M to repay Avenue debt (12.5% interest); expected to extend cash runway into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/0001104659-26-055411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000110465926055411/tm2613584d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer